stockrowOrchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024.
- Revenue
- −89.5%
- EPS
- +24.0%
- Free cash flow
- −25.9%
- Total debt
- +142.2%
Quarter to June 2026, against a year earlier
Follow OBIO
Alert me
Orchestra BioMed Holdings, Inc. (OBIO) EV/Sales
As of 6 November 2026, Orchestra BioMed Holdings, Inc. (OBIO) trades at a EV/Sales of 9.0×. Over the past ten years it has ranged from 0.0× (December 2022) to 129× (April 2023); the current reading is higher than 49% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.2× | (91.19%) |
| FY2024 | 35.9× | (51.69%) |
| FY2023 | 74.4× | 244.80% |
| FY2022 | 21.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.3× | 10.05% |
| Mar 2026 | 5.7× | 80.18% |
| Dec 2025 | 3.2× | (81.36%) |
| Sep 2025 | 17.0× | (40.08%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | 0.4× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 1.8× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. | 9.0× |
| SRZN Surrozen, Inc. compare | 22.7× |
| IRD Opus Genetics, Inc. compare | 35.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)